TD2 And Deep Lens Partner To Enable Diversity, Access And Faster Clinical Trial Enrollment For Community Oncology Practices
SCOTTSDALE, Ariz.–(BUSINESS WIRE)–Translational Drug Development (TD2), a leading precision oncology contract research organization (CRO), and Deep Lens have announced a strategic partnership that will enhance access to tailored oncology treatments…